MedTrace Logo

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

NCT03367299 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2025-01-22

No results posted yet for this study

Summary

The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.

Conditions

  • Acute Lymphoid Leukemia
  • Philadelphia Chromosome-Negative B-Cell Precursor

Interventions

DRUG

Chemotherapy + Blinatumomab

Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Renato Bassan · Azienda ULSS 12 "Veneziana" U.O. Ematologia Direttore Renato Bassan

  • Roberto Foà · Policlinico Umberto I, Hematology Department.

  • Alessandro Rambaldi · Ospedale di Bergamo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-08
Primary Completion
2024-09-02
Completion
2024-09-02
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03367299 on ClinicalTrials.gov